Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746619 | 0.91 | ALDH1A1 (0.50) | ALDH1A1HPGDPHF8KDM2AFFAR3 | |
| SCHEMBL8786970 | 0.88 | ALDH1A1 (0.48) | ALDH1A1HPGDPHF8KDM2AFFAR3 | |
| SCHEMBL5353880 | 0.86 | ALDH1A1 (0.55) | ALDH1A1HPGDLMNAAKR1B1KDM4C | |
| SCHEMBL10787440 | 0.86 | AKR1B1 (0.50) | ALDH1A1CA12CA9AKR1B1KDM4C | |
| SCHEMBL21675651 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HPGDPHF8KDM2AFFAR3 | |
| SCHEMBL8643046 | 0.83 | GPR84 (0.56) | ALDH1A1PHF8AKR1B1KDM4CKDM5A | |
| SCHEMBL14566020 | 0.83 | GPR84 (0.56) | ALDH1A1PHF8AKR1B1KDM4CKDM5A | |
| SCHEMBL6870561 | 0.83 | GPR84 (0.56) | ALDH1A1PHF8AKR1B1KDM4CKDM5A | |
| SCHEMBL527256 | 0.83 | GPR84 (0.56) | ALDH1A1PHF8AKR1B1KDM4CKDM5A | |
| SCHEMBL31273343 | 0.83 | GPR84 (0.56) | ALDH1A1PHF8AKR1B1KDM4CKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112624843-A | Slow-release carbon-based compound fertilizer and production method thereof | 李娜 | 2021-04-09 | — | — | CN | disclosed |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-21 | — | — | US | disclosed |
| US-9067881-B2 | 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives | NOVARTIS AG (CH) | 2015-06-30 | — | — | US | disclosed |
| EP-2668159-A1 | 4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303538-A1 | 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives | NOVARTIS PHARMA AG (CH) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101058-A1 | 4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20080306136-A1 | Substituted Ureas and Carbamates | ELAN PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-7351738-B2 | Substituted ureas and carbamates | ELAN PHARMACEUTICALS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| CN-100366605-C | Compounds to treat alzheimer's disease | ELAN PHARM INC (US) | 2008-02-06 | — | — | CN | disclosed |
| CN-101090883-A | Substituted hydroxyethylamines | ELAN PHARM INC (US) | 2007-12-19 | — | — | CN | disclosed |
| US-5270331-A | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides | PFIZER, INC. (US) | 1993-12-14 | — | — | US | disclosed |
| US-4921942-A | Organometallic compounds | STEPAN COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4724174-A | AMIDO CARBOXYL SOAPS; FILM-FORMING; SUBSTANTIVITY | STEPAN COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4705666-A | Alkanolamin salts of alkenyl succinic acid dialkyl semiamide corrosion inhibitors | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1987-11-10 | — | — | US | disclosed |
| US-4675422-A | ALUMINUM COATINGS | STEPAN COMPANY (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0220934-A2 | Aluminium carboxylates | STEPAN COMPANY (US) | 1987-05-06 | — | — | EP | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0010941-B1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
| US-4221787-A | Esteramide prodrugs of anti-inflammatory corticosteroids | INTERX RESEARCH CORPORATION (US) | 1980-09-09 | — | — | US | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303538-A1 | 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives | TPH1, IDO1, TPH2 | ALDH1A1 224/4885HPGD 919/4885PHF8 2303/4885 |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | ADCY7, ADCY1, ADCY9 | ALDH1A1 716/4885HPGD 2417/4885PHF8 2234/4885 |
| US-20080306136-A1 | Substituted Ureas and Carbamates | BACE1, BACE2, APP | ALDH1A1 2203/4885HPGD 2647/4885PHF8 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.